Cargando…

Simultaneous development of Graves’ disease and type 1 diabetes during anti‐programmed cell death‐1 therapy: A case report

We present the first case of simultaneous development of Graves’ disease and type 1 diabetes during anti‐programmed cell death 1 therapy. A 48‐year‐old man with parotid gland adenocarcinoma and lung metastasis had received five courses of nivolumab. Fourteen days after administration of the sixth co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurihara, Susumu, Oikawa, Yoichi, Nakajima, Ritsuko, Satomura, Atsushi, Tanaka, Ryuhei, Kagamu, Hiroshi, Shimada, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378416/ https://www.ncbi.nlm.nih.gov/pubmed/31926048 http://dx.doi.org/10.1111/jdi.13212

Ejemplares similares

Administration of thiamazole for Graves’ disease might trigger the onset of type 1 diabetes
por: Mizutani, Gen, et al.
Publicado: (2018)

HLA typing of patients who developed subacute thyroiditis and Graves’ disease after SARS-CoV-2 vaccination: a case report
por: Yasuda, Shigemitsu, et al.
Publicado: (2023)

Intrinsic insulin secretion capacity might be preserved by discontinuing anti‐programmed cell death protein 1 antibody treatment in ‘anti‐programmed cell death protein 1 antibody‐induced’ fulminant type 1 diabetes
por: Sakai, Gota, et al.
Publicado: (2018)

Bodyweight threshold for sudden onset of ketosis might exist in ketosis‐prone type 2 diabetes patients
por: Satomura, Atsushi, et al.
Publicado: (2019)

HbA1c level may be a risk factor for oxygen therapy requirement in patients with coronavirus disease 2019
por: Yanagisawa, Shinnosuke, et al.
Publicado: (2022)

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
por: Mouri, Atsuto, et al.
Publicado: (2021)

Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)
por: Awata, Takuya, et al.
Publicado: (2017)

Clinical features resembling subcutaneous insulin resistance observed in a patient with type 2 diabetes and severe COVID-19-associated pneumonia: a case report
por: Satomura, Atsushi, et al.
Publicado: (2021)

Combination of anti‐CD25 antibody and poly I:C treatment in pregnant NOD mice may be used as ‘pregnancy‐related’ type 1 diabetes model
por: Shimada, Akira, et al.
Publicado: (2022)

Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter
por: Kataoka, Hiroshi, et al.
Publicado: (2021)

On‐label use of sodium–glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes
por: Horii, Takeshi, et al.
Publicado: (2021)

Death of Dr. Graves
Publicado: (1853)

Graves’ disease and mental disorders
por: Fukao, Atsushi, et al.
Publicado: (2019)

Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers
por: Aoki, Takahiro, et al.
Publicado: (2016)

Simultaneous induction of Graves’ hyperthyroidism and Graves’ ophthalmopathy by TSHR genetic immunization in BALB/c mice
por: Xia, Nan, et al.
Publicado: (2017)

Actual condition survey regarding mismatch of measurements between radioimmunoassay and enzyme‐linked immunosorbent assay tests for anti‐glutamic acid decarboxylase antibody in real‐world clinical practice
por: Oikawa, Yoichi, et al.
Publicado: (2018)

Programmed Cell Death-Ligand 1 (PD-L1) gene Single Nucleotide Polymorphism in Graves’ Disease and Hashimoto’s Thyroiditis in Korean Patients
por: Yoon, Jee Hee, et al.
Publicado: (2021)

A Case Report of Graves' Disease Induced by the Anti-Human Programmed Cell Death-1 Monoclonal Antibody Pembrolizumab in a Bladder Cancer Patient
por: Yajima, Ken, et al.
Publicado: (2019)

Thyrotropin-producing pituitary adenoma simultaneously existing with Graves’ disease: a case report
por: Arai, Nobuhiko, et al.
Publicado: (2017)

Real‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan
por: Horii, Takeshi, et al.
Publicado: (2023)

Title: Case of Hyperthyroidism in a Patient on Anti-PD-1 (Programmed Cell Death Receptor-1 Blocking Antibody) Therapy Caused by Destructive Thyroiditis Followed by Graves’ Disease
por: Reddy, Chandrika, et al.
Publicado: (2021)

A case of simultaneous occurrence of Graves’ disease and Hashimoto's thyroiditis
por: Majumder, Anirban, et al.
Publicado: (2012)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Negative influence of programmed death‐1‐ligands on the survival of esophageal cancer patients treated with chemotherapy
por: Tanaka, Koji, et al.
Publicado: (2016)

Characteristics of Gut Microbiota in Patients With Diabetes Determined by Data Mining Analysis of Terminal Restriction Fragment Length Polymorphisms
por: Nakamura, Yuta, et al.
Publicado: (2019)

Value of (18)F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy
por: Castellanos, Emily H., et al.
Publicado: (2017)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study
por: Horii, Takeshi, et al.
Publicado: (2020)

Acute kidney injury in Japanese type 2 diabetes patients receiving sodium–glucose cotransporter 2 inhibitors: A nationwide cohort study
por: Horii, Takeshi, et al.
Publicado: (2021)

Real‐world risk of lower‐limb amputation associated with sodium–glucose cotransporter 2 inhibitors versus metformin: A propensity score‐matched model analysis in Japan
por: Mizutani, Gen, et al.
Publicado: (2022)

Rare presentation of Graves’ disease with myalgia: A case report
por: Kurihara, Masaru, et al.
Publicado: (2021)

Safety and efficacy of simultaneous colorectal ESD for large synchronous colorectal lesions
por: Chiba, Hideyuki, et al.
Publicado: (2017)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

A Case of Thyrotoxicosis due to Simultaneous Occurrence of Subacute Thyroiditis and Graves' Disease
por: Kageyama, Kazunori, et al.
Publicado: (2018)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kurokawa, Masayuki, et al.
Publicado: (2023)

Anti-tumor immunity enhancement by photodynamic therapy with talaporfin sodium and anti-programmed death 1 antibody
por: Sasaki, Makiko, et al.
Publicado: (2023)

Higher Body Mass Index and Increased Prevalence of Paranasal Sinus Disease
por: Kabeya, Yusuke, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k1gu8641g56mnmvfjn9dcujdiq